Clodronate inhibits angiogenesis in vitro and in vivo

Oncology Reports

Volumn 19, Issue 5, 2008, Pages 1109-1112

  Ribatti, Domenico ^a   Maruotti, N ^b   Nico, B ^a   Longo, V ^a   Mangieri, D ^a   Vacca, A ^c   Cantatore, F P ^b  

^a Department of Human Anatomy and Histology ^*  (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Antiangiogenesis; Bisphosphonate; Chorioallantoic membrane; Clodronate; Endothelial cells

Indexed keywords

CLODRONIC ACID; FIBROBLAST GROWTH FACTOR 2; MATRIGEL; ANGIOGENESIS INHIBITOR; BONE DENSITY CONSERVATION AGENT; COLLAGEN; LAMININ; PROTEOGLYCAN;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ELONGATION; CELL PROLIFERATION; CELL SHAPE; CELL STRUCTURE; CHICK EMBRYO; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MORPHOGENESIS; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CAPILLARY; CHEMISTRY; CHORIOALLANTOIS; DRUG COMBINATION; INFLAMMATION; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHASE CONTRAST MICROSCOPY; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CAPILLARIES; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; CLODRONIC ACID; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; INFLAMMATION; LAMININ; MICROSCOPY, PHASE-CONTRAST; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS;

EID: 47549113482     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.5.1109     Document Type: Article

References (21)

1. Shinada H, Adamek G, Felix R, Fleisch H, Schenk R and Hagon H: Structure-activity relationships of various bisphophonates. Calcif Tissue Int 35: 87-99, 1983.
2. Benford HL, Fith JC, Auriola S, Monkkonen J and Bogers MJ: Farnesol and geranylgeraniol prevent activation of caspase by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56: 131-140, 1999.
3. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061, 2002.
4. Wood J, Schnell C and Green JR: Zoledronic acid, a potent inhibitor of bone resorption inhibits proliferation and induces apotosis in human endothelial cells in vitro and is anti-angiogenic in a murine growth factor implant model. Proc Am Soc Clin Oncol 9: 664 Abs. 2620, 2000.
5. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M and Clezardin P: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostrate in castrated rats. Cancer Res 62: 6538-6544, 2002.
6. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V and Tonini G: Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 8: 1080-1094, 2002.
7. Bezzi M, Hasmim M, Bieler G, Dormond O and Ruegg C: Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 44: 43603-43614, 2003.
8. Ribatti D, Nico B, Mangieri D, Maruotti N, Longo V, Vacca A and Cantatore FP: Neridronate inhibits angiogenesis in vitro and in vivo. Clin Rheumatol 26: 1094-1098, 2007.
9. Ribatti D, Nico B, Vacca A and Presta M: The gelatin sponge-chorioallantoic membrane assay. Nat Protocols 1: 85-91, 2006.
10. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Pellegrino A and Dammacco F: Angiogenesis is produced by non-toxic doses of vinblastine. Blood 94: 4143-4155, 1999.
11. Kueng K, Silfer E and Eppenberger V: Quantitation of cells cultured on 96-well plates. Ann Biochem 182: 16-19, 1989.
12. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
13. Folkinan J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
14. Brown DL and Robbins R: Developments in the therapeutic applications of bisphosphonates. J Clin Pharmacol 39: 651-660, 1999.
15. Green JR: Antitumor effects of bisphosphonates. Cancer 97 (Suppl 3): 840-847, 2003.
16. Ylitalo R, Kalliovalkama J, Wu X, Kankaanranta H, Salenius JP, Sisto T, Lahteenmaki T, Ylitalo P and Porsti I: Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol 83: 125-131, 1998.
17. Hamma-Kourbali Y, Di Benedetto M, Ledoux D, Oudar O, Leurox Y, Lecouvey M and Kraemer M: A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun 310: 816-823, 2003.
18. Sebbah-Louriki M, Colombo BM, el Manouni D, Martin A, Salzmann JL, Leroux Y, Perret GY and Crepin M: A new phenylacetate-bisphoshonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. Anticancer Res 22: 3925-3931, 2002.
19. Yamagishi S, Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, Nakamura H, Shimizu T, Takeuchi M, Yoshimura A, Bucala R, Shimizu H and Imaizumi T: Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 165: 1865-1874, 2004.
20. Zeisberger SM, Odermatt B, Marty C, Zehnder AHM, Ballmer-Hofer K and Schwendener RA: Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95: 272-281, 2006.
21. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, Grilli C, Virzi V, Gasparro S, Rocci L and Tonini G: Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25: 144-151, 2005.